Hospital
Avera Granite Falls
Avera Granite Falls was paid $2.17M by Medicaid between Jan 2020 and Dec 2024, across 55 billing codes. Its largest line is A0427, emergency ambulance ride, advanced life support — 21% of everything it billed.
33Billing provider infoAVERA GRANITE FALLS
GRANITE FALLS, MN 56241
GRANITE FALLS, MN 56241
33aNPI1700429610assigned 10/23/2019
33bProvider typeCritical Access Hospital
28Total paid$2.17M
24GClaims36,957
24DCodes billed55
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Minnesota
Rank by total paid#20 of 68
Median peer was paid$798K
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 5,887 | $209K | |
| 2021 | 8,183 | $565K | |
| 2022 | 9,320 | $628K | |
| 2023 | 8,724 | $460K | |
| 2024incomplete | 4,843 | $310K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 21% | 606 | 471 | $454K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 7,845 | 6,540 | $390K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 7,335 | 6,292 | $256K |
| A0425 | Ground mileage, per statute mile | 12% | 979 | 711 | $255K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.3% | 950 | 737 | $114K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.7% | 563 | 382 | $102K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.1% | 777 | 605 | $89K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 1,158 | 996 | $87K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 3,452 | 2,469 | $64K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 1,436 | 1,194 | $62K |
| 36415 | Collection of venous blood by venipuncture | 2.7% | 4,402 | 3,553 | $59K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 837 | 321 | $56K |
43 more codes
| 80053 | Comprehensive metabolic panel | 1.2% | 532 | $26K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.0% | 248 | $22K |
| 90837 | Psychotherapy session, about an hour | <1% | 495 | $18K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 473 | $12K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 758 | $11K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 71 | $10K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 174 | $9K |
| 96127 | <1% | 311 | $8K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 150 | $7K |
| 99285 | Emergency room visit (most serious) | <1% | 24 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 536 | $7K |
| S0209 | Wheelchair van, mileage, per mile | <1% | 77 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 98 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 67 | $4K |
| 11721 | <1% | 340 | $3K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 52 | $3K |
| J3490 | Unclassified drugs | <1% | 146 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 57 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 69 | $2K |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 15 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 33 | $2K |
| 80061 | Lipid panel | <1% | 39 | $2K |
| 90686 | <1% | 252 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 273 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 69 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 34 | $1K |
| A0130 | Non-emergency transportation: wheelchair van | <1% | 77 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13 | $1K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 28 | $995.90 |
| 90662 | <1% | 30 | $910.44 | |
| 81001 | <1% | 27 | $742.78 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 69 | $672.31 |
| A9270 | Non-covered item or service | <1% | 545 | $665.81 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14 | $445.18 |
| 92551 | <1% | 66 | $391.26 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 66 | $389.23 |
| 85018 | <1% | 13 | $240.58 | |
| 99173 | <1% | 69 | $200.22 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 148 | $184.79 |
| 90656 | <1% | 16 | $84.35 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 12 | $17.65 |
| 90651 | 0% | 17 | $0.00 | |
| 99188 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTREIER, DEBRA (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Avera Granite Falls | Granite Falls, MN | $525K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.